Pharmacological agents are being developed to modulate phosphotyrosyl (pTyr)-dependent cell signalling. Emphasis is on inhibitors of pTyr-dependent binding interactions which are mediated by """"""""src homology 2"""""""" (SH2) domains or """"""""phosphotyrosine-interaction domains"""""""" (PIDs) and on protein-tyrosine phosphatase (PTP) inhibitors. Central to both of these efforts is the development of new pTyr mimetics which afford either increased stability toward enzymatic degradation by PTPs or increased affinity. Among SH2 domain-directed ligands developed during the reporting period are heteroaryl-containing pTyr mimetics based on the structure of the differentiating antibiotic azatyrosine, which are designed to afford higher affinity and specificity. Additionally, a new amino acid has been prepared, which effectively constrains a tyrosyl residue to the conformation required for binding to an SH2 domain, as determined by x-ray crystallography. A major obstacle to SH2 inhibitor development is poor cellular penetration of inhibitors due to the requirement for high binding affinity of either a pTyr or other doubly ionized residue. Work is currently underway to prepare a new class of peptidomimetics as SH2 domain inhibitors which do not require this doubly-charged pTyr pharmacophore. In the phosphatase area, new PTP inhibitors have been designed and synthesized based on the x-ray structure of our lead small molecule inhibitor bound to the PTP1B enzyme. A 100% increase in affinity relative to the parent inhibitor has resulted for the first analogue in the series. Additional peptide-peptidomimetic hybrids have been prepared using solid-phase chemistry. Collaborations are in place to determine x-ray structures of new inhibitors bound to relevant phosphatases, and to utilize this information for the design of a new generation of inhibitors having enhanced binding interactions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC006198-07
Application #
2463718
Study Section
Special Emphasis Panel (LMC)
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1996
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Liu, Fa; Park, Jung-Eun; Qian, Wen-Jian et al. (2011) Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat Chem Biol 7:595-601
Liu, Fa; Park, Jung-Eun; Lee, Kyung S et al. (2009) Preparation of orthogonally protected (2S, 3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) as a phosphatase-stable phosphothreonine mimetic and its use in the synthesis of Polo-box domain-binding peptides. Tetrahedron 65:9673-9679
Jiang, Sheng; Liao, Chenzhong; Bindu, Lakshman et al. (2009) Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity. Bioorg Med Chem Lett 19:2693-8
Cao, Xuefei; Plasencia, Carmen; Kanzaki, Atsuko et al. (2009) Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis. Curr Cancer Drug Targets 9:189-201
Liu, Fa; Worthy, Karen M; Bindu, Lakshman K et al. (2007) Structural examination of ring-closing metathesis-derived 15-member macrocycles as Grb2 SH2 domain-binding tetrapeptide mimetics. J Org Chem 72:9635-42
Giubellino, Alessio; Gao, Yang; Lee, Sunmin et al. (2007) Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res 67:6012-6
Kang, Sang-Uk; Choi, Won Jun; Oishi, Shinya et al. (2007) Examination of acylated 4-aminopiperidine-4-carboxylic acid residues in the phosphotyrosyl+1 position of Grb2 SH2 domain-binding tripeptides. J Med Chem 50:1978-82
Choi, Won Jun; Shi, Zhen-Dan; Worthy, Karen M et al. (2006) Application of azide-alkyne cycloaddition 'click chemistry' for the synthesis of Grb2 SH2 domain-binding macrocycles. Bioorg Med Chem Lett 16:5265-9
Dharmawardana, Pathirage G; Peruzzi, Benedetta; Giubellino, Alessio et al. (2006) Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anticancer Drugs 17:13-20
Yao, Zhu-Jun; Lee, Kyeong; Burke Jr, Terrence R (2005) Incorporation of phosphotyrosyl mimetic 4-(phosphonodifluoromethyl)phenylalanine (F2Pmp) into signal transduction-directed peptides. Methods Mol Biol 298:91-103

Showing the most recent 10 out of 37 publications